

GOG-3073, ENGOT-OV72/MITO: A PHASE 3 STUDY OF RELACORILANT + NAB-PACLITAXEL VS. NAB-PACLITAXEL IN PLATINUM-RESISTANT OVARIAN CANCER




PRESENTER:
Dr. Jae-Weon Kim, MD, PhD
Contact: kjwks@gmail.com

Domenica Lorusso¹, Andrea Bagameri², Erin Bishop³, Anita Chudecka-Glaz⁴, Alix Devaux⁵, Laurence Gladieff⁶, Mary E. Gordinier⁷, Jae-Weon Kim⁸, Jacob Korach⁹, Michael E. McCollum¹⁰, Linda Mileschkin¹¹, Bradley J. Monk¹², Shibani Nicum¹³, Angelica Nogueira-Rodrigues¹⁴, Ana Oaknin¹⁵, David O'Malley¹⁶, Mauro Orlando¹⁷, Lyndah Dreiling¹⁸, Iulia Cristina Tudor¹⁸, Alexander B. Olawaiye¹⁹

¹Fondazione Policlinico Universitario A. Gemelli IRCCS and Catholic University of Sacred Heart, Rome Italy; ²National Institute of Oncology, Budapest, Hungary; ³Medical College of Wisconsin, Milwaukee, United States; ⁴Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland; ⁵Oncology Department of Grand Hôpital de Charleroi, Charleroi, Belgium; ⁶Institut Claudius Regaud, IUCT Oncopole, Toulouse, France; ⁷Norton Cancer Institute, Louisville, United States; ⁸Department of Obstetrics and Gynecology, Seoul National University, Seoul, South Korea; ⁹Shiva Medical Center, Tel Aviv University, Tel Aviv, Israel; ¹⁰Virginia Oncology Associates, Norfolk, United States; ¹¹Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia; ¹²University of Arizona College of Medicine, Creighton University School of Medicine, HonorHealth Research Institute, GOG-Foundation, GOG-Partners, Scottsdale, United States; ¹³University College London Cancer Institute, London, United Kingdom; ¹⁴Federal University Of Minas Gerais, Dom Oncologia And Oncoclinicas - Brazil, Belo Horizonte, Brazil; ¹⁵Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain; ¹⁶The Ohio State University and the James Cancer Center, GOG, Columbus, United States; ¹⁷Instituto Alexander Fleming, Buenos Aires, Argentina; ¹⁸Corcept Therapeutics, Inc., Menlo Park, United States; ¹⁹University of Pittsburgh, Pittsburgh, United States.

Background

- Platinum resistance occurs in virtually all patients with recurrent ovarian cancer.
- Single agent chemotherapies are commonly used in this setting, but outcomes are generally poor, leaving a large unmet need for treatments.
- Cortisol**, which acts by binding to the **glucocorticoid receptor (GR)**, can reduce the efficacy of chemotherapies by suppressing the apoptotic pathways used by cytotoxic agents.
- The GR is abundantly expressed in ovarian tumors and high GR expression is associated with poor outcomes.¹
- Preclinical and clinical data indicate that modulation of GR signaling with **relacorilant**, a selective GR modulator, can reverse the anti-apoptotic effects of cortisol, thereby enhancing chemotherapy efficacy.²⁻⁴




A phase 2 study* of relacorilant + nab-paclitaxel in patients with recurrent, platinum-resistant/refractory ovarian cancer showed:⁴

- Improved PFS (HR 0.66; *P*=0.038; median PFS 5.6 vs. 3.8 months)
 - Improved DOR (HR 0.36; *P*=0.006; median DOR 5.6 vs. 3.7 months)
 - Trend toward improved OS (HR 0.67; median OS 13.9 vs. 12.2 months)
 - Even greater improvement was seen in patients with 1–3 prior lines of therapy (including prior bevacizumab) and without primary platinum-refractory disease.
- **The phase 3 ROSELLA study** aims to confirm the findings of the phase 2 study in a larger patient population.

*Relacorilant dosed intermittently on the day before, day of, and day after nab-paclitaxel infusion; compared to nab-paclitaxel monotherapy. Results presented reflect data as of March 22, 2021 (PFS and DOR) and March 7, 2022 (OS). DOR, duration of response; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

Study Design

- ROSELLA** (NCT05257408, EudraCT 2022-000662-18) is a confirmatory, phase 3, randomized, 2-arm, open-label, multicenter study of relacorilant + nab-paclitaxel compared to nab-paclitaxel monotherapy in patients with recurrent, platinum-resistant, high-grade serous epithelial ovarian, primary peritoneal, or fallopian tube cancer.
- The study is being conducted globally in collaboration with



- Approximately 360 patients randomized 1:1 to:
 - Relacorilant (150 mg the day before, day of, and day after nab-paclitaxel infusion) + nab-paclitaxel (80 mg/m² on days 1, 8, and 15 of each 28-day cycle)or
 - Nab-paclitaxel monotherapy (100 mg/m² on days 1, 8, and 15 of each 28-day cycle).

Primary Endpoint

- Progression-free survival by BICR per RECIST v1.1

Key Secondary & Exploratory Endpoints

- Overall survival per RECIST v1.1
- Safety, pharmacodynamics, pharmacokinetics, and patient-reported outcomes

BICR, blinded independent central review; RECIST, Response Evaluation Criteria in Solid Tumors.

Key Inclusion & Exclusion Criteria

Inclusion Criteria	Exclusion Criteria
<ul style="list-style-type: none">≥18 years old	
<ul style="list-style-type: none">Diagnosis:<ul style="list-style-type: none">High-grade (grade 3) serous, epithelial ovarian, primary peritoneal, or fallopian tube carcinoma	<ul style="list-style-type: none">Diagnosis:<ul style="list-style-type: none">Low-grade endometrioid, clear-cell carcinoma, mucinous or sarcomatous histology, or mixed tumors containing any of these histologies, or low-grade or borderline ovarian tumor
<ul style="list-style-type: none">Platinum-resistant disease (progression <6 months from completion of a platinum-containing therapy)	<ul style="list-style-type: none">Primary platinum-refractory disease
<ul style="list-style-type: none">Prior therapies:<ul style="list-style-type: none">1–3 lines of prior systemic anticancer therapy≥1 prior line of platinum chemotherapy and prior bevacizumab required	<ul style="list-style-type: none">Prior therapies:<ul style="list-style-type: none">Chemotherapy and other treatments for disease under study within 28 days before the first dose
<ul style="list-style-type: none">ECOG performance score of 0 or 1Adequate organ function:<ul style="list-style-type: none">Absolute neutrophil count ≥1500 cells/mm³Platelet count ≥100,000/mm³Hemoglobin ≥9 g/dLAST or ALT ≤2.5 × ULN or ≤5 × ULN in context of liver metastasesTotal bilirubin ≤1.5 × ULNAlbumin ≥3 g/dLCreatinine clearance ≥40 mL/min/1.73 m²	<ul style="list-style-type: none">Clinically relevant toxicity from prior systemic anticancer therapies or radiotherapy that has not resolved to grade ≤1Any major surgery within 4 weeks prior to randomizationTreatment with chronic or frequently used corticosteroids<ul style="list-style-type: none">A short course of steroids for hypersensitivity reactions due to chemotherapy (eg, paclitaxel) is allowed

ALT, alanine aminotransferase; AST, aspartate aminotransferase; ECOG, Eastern Cooperative Oncology Group; ULN, upper limit of normal.

Summary & Conclusions

- There remains a large unmet need for effective treatments for platinum-resistant ovarian cancer.
- A phase 2 study of the selective glucocorticoid receptor modulator relacorilant + nab-paclitaxel in patients with advanced ovarian cancer showed meaningful improvements in PFS, DOR, and OS with minimal added toxicity compared to nab-paclitaxel alone.⁴
- Here we introduce ROSELLA, a confirmatory phase 3 study comparing relacorilant + nab-paclitaxel to nab-paclitaxel monotherapy in patients with advanced, platinum-resistant ovarian cancer.

DOR, duration of response; PFS, progression-free survival; OS, overall survival.

The authors want to thank all those who are participating in this study: The study patients and their families, the investigators, and the sponsor team.

References

- Veneris, JT et al. *Gynecol Onol.* 2017;146(1):153–160.
- Greenstein, AE and Hunt, HJ. *Oncotarget.* 2021;12(13): 1243–1255.
- Munster, P et al. *Clin Cancer Res.* 2022;28(15):3214–3224.
- Colombo, N et al. *J Clin Oncol.* 2023 Jun 26;JCO20202624.

Acknowledgements

This study is sponsored by Corcept Therapeutics. Medical writing assistance was provided by Tina Schlafly, PhD, CMPP, and Valerie Hilliard, PhD, of Corcept Therapeutics.

Presenter Disclosures

No relationships to disclose.